Do You Believe in the Growth Trajectory of Boston Scientific Corporation (BSX)?

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) returned -8.59% (net of fees), outperforming the Russell 1000 Growth Index’s -9.97% decline. In the first quarter, post-election optimism, driven by reduced regulation and a business-friendly environment, drifted away to concerns over fiscal and tariff uncertainties, which increased volatility and raised fears of a recession. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its first-quarter 2025 investor letter, Parnassus Growth Equity Fund highlighted stocks such as Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) manufactures and markets medical devices for use in various interventional medical specialties. The one-month return of Boston Scientific Corporation (NYSE:BSX) was -0.65%, and its shares gained 35.80% of their value over the last 52 weeks. On June 26, 2025, Boston Scientific Corporation (NYSE:BSX) stock closed at $104.58 per share with a market capitalization of $154.721 billion.

Parnassus Growth Equity Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q1 2025 investor letter:

"Boston Scientific Corporation (NYSE:BSX), a medical device company, continued to report exceptionally strong growth led by its existing Watchman heart implant franchise and its recently launched Farapulse franchise. We expect the company’s robust growth trajectory to continue in upcoming years, given the potential market for Farapulse, a promising treatment for atrial fibrillation."

Boston Scientific Corporation (NYSE:BSX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 108 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the first quarter, which was 96 in the previous quarter. Boston Scientific Corporation’s (NYSE:BSX) reported revenue of $4.663 billion, reflecting a 20.9% growth compared to Q1 2024. While we acknowledge the potential of Boston Scientific Corporation (NYSE:BSX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.

In another article, we covered Boston Scientific Corporation (NYSE:BSX) and shared the list of best stocks to invest in for a month. Boston Scientific Corporation (NYSE:BSX) contributed to Baron Health Care Fund's performance during Q1 2025. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.